Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient WithETV6-NTRK3Fusion-Positive Carcinoma Harboring theNTRK3G623RSolvent-Front Mutation

Authors :: Daniela Richter
G. Folprecht
Christoph Heining
Karin Laaber
Heiner Nebelung
Sebastian Uhrig
Daniela Aust
Stefan Frohling
Barbara Hutter
Arne Jahn
Hanno Glimm
Friederike Herbst
Dorothea Hanf
Source :: JCO Precision Oncology. :687-694
Publication Year :: 2021
Publisher :: American Society of Clinical Oncology (ASCO), 2021.

Subjects :: Cancer Research
Cabozantinib
business.industry
Entrectinib
medicine.disease
chemistry.chemical_compound
ETV6
Oncology
chemistry
Mutation (genetic algorithm)
Carcinoma
medicine
Cancer research
business

Tools